Regeneron’s Eylea (aflibercept) Injection Receives FDA’s Approval for Diabetic Retinopathy

 Regeneron’s Eylea (aflibercept) Injection Receives FDA’s Approval for Diabetic Retinopathy

Regeneron’s Eylea (aflibercept) Injection Receives FDA’s Approval for Diabetic Retinopathy

Shots:

  • The approval is based on P-III PANORAMA study results assessing Eylea (q8w, q16w) vs sham in 402 patients with non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME)
  • The P-III PANORAMA study results: improvement on DRSS score by ≥2‑step (80%,65% vs 15%); @q16w & @q8w, reduction in risk (85% & 88%); @q8w, improvement in diabetic retinopathy (80%) respectively
  • Eylea (aflibercept, q8w & q16w) injection is a VEGF inhibitor, blocking the growth of new blood vessels, reduces vascular permeability in the eye by targeting VEGF-A & PLGF and has received FDA’s approval for multiple indications including wet age-related macular degeneration and DR with DME

Click here to read full press release/ article | Ref: Regeneron | Image: WCSA WORLD

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post